ASP Isotopes (NASDAQ:ASPI) Shares Gap Up After Analyst Upgrade

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) gapped up prior to trading on Thursday after Canaccord Genuity Group raised their price target on the stock from $8.50 to $11.00. The stock had previously closed at $7.76, but opened at $7.98. Canaccord Genuity Group currently has a buy rating on the stock. ASP Isotopes shares last traded at $8.20, with a volume of 721,649 shares trading hands.

Insider Buying and Selling

In other news, CEO Paul Elliot Mann sold 316,666 shares of the stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $1,779,662.92. Following the completion of the sale, the chief executive officer now directly owns 7,315,454 shares in the company, valued at $41,112,851.48. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Robert Ainscow sold 66,668 shares of the business's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $374,674.16. Following the completion of the transaction, the chief operating officer now owns 1,419,992 shares in the company, valued at approximately $7,980,355.04. The trade was a 4.48% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 766,667 shares of company stock valued at $4,358,502 over the last ninety days. 21.40% of the stock is owned by company insiders.

Institutional Trading of ASP Isotopes

A number of large investors have recently bought and sold shares of ASPI. JPMorgan Chase & Co. lifted its stake in shares of ASP Isotopes by 854.6% in the 4th quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company's stock valued at $960,000 after purchasing an additional 189,697 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in ASP Isotopes by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 21,646 shares of the company's stock worth $99,000 after purchasing an additional 2,757 shares in the last quarter. Avantax Advisory Services Inc. acquired a new position in ASP Isotopes in the fourth quarter valued at approximately $45,000. Wells Fargo & Company MN boosted its holdings in shares of ASP Isotopes by 57.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,472 shares of the company's stock worth $111,000 after buying an additional 8,925 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in shares of ASP Isotopes during the 4th quarter worth approximately $113,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

ASP Isotopes Stock Down 7.5%

The firm's 50 day moving average price is $5.65 and its two-hundred day moving average price is $5.44. The company has a market cap of $596.29 million, a P/E ratio of -13.01 and a beta of 3.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.